Breaking News Instant updates and real-time market news.

DWDP

DowDuPont

$39.24

0.36 (0.93%)

, TEL

TE Connectivity

$88.64

1.06 (1.21%)

08:03
04/17/19
04/17
08:03
04/17/19
08:03

DowDuPont announces new members for future Board of Directors of DuPont

DowDuPont (DWDP) announced three additional members to the future board of directors of DuPont, currently the Specialty Products Division of DowDuPont. The new directors include Frank Clyburn, chief commercial officer at Merck & Co. (MRK), Terrence Curtin, CEO of TE Connectivity (TEL), and Frederick Lowery, senior vice president and president, Life Sciences Solutions and Laboratory Products at Thermo Fisher Scientific (TMO). With these additions, DuPont expects to have 12 members on its board, effective June 1.

DWDP

DowDuPont

$39.24

0.36 (0.93%)

TEL

TE Connectivity

$88.64

1.06 (1.21%)

MRK

Merck

$77.50

-1.01 (-1.29%)

TMO

Thermo Fisher

$266.00

-11.755 (-4.23%)

  • 17

    Apr

  • 17

    Apr

  • 24

    Apr

  • 24

    Apr

  • 30

    Apr

  • 02

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 18

    May

  • 29

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 16

    Jul

  • 06

    Aug

  • 20

    Sep

DWDP DowDuPont
$39.24

0.36 (0.93%)

04/08/19
RHCO
04/08/19
NO CHANGE
Target $41
RHCO
Hold
DowDuPont price target lowered to $41 from $57 at SunTrust
SunTrust analyst James Sheehan lowered his price target on DowDuPont to $41 to reflect the impact of its Material Science spin into Dow Inc. The analyst also keeps his Hold rating on the shares, stating that while he is positive on the optionality of the company's portfolio and the prospects for improved ROIC, he expects DowDuPont shares to trade rangebound ahead of its Agriculture Division and until there is better visibility of a macro recovery.
04/16/19
RBCM
04/16/19
DOWNGRADE
RBCM
Sector Perform
DowDuPont downgraded to Sector Perform from Outperform at RBC Capital
04/16/19
04/16/19
DOWNGRADE
Target $40

Sector Perform
DowDuPont downgraded to Sector Perform at RBC Capital on Dow spinoff impact
As previously reported, RBC Capital analyst Arun Viswanathan downgraded DowDuPont to Sector Perform from Outperform and lowered his price target to $40 from $61, citing the impact of the company's spinoff of Dow on April 2nd. The analyst believes that DowDuPont's focus on its Specialty division opens it to the economic macro concerns in Europe and China. Viswanathan also points to the continued weakness in the company's Agriculture segment following the March floods in the Midwest as well as the separation costs related to the Dow spin and Corteva spin in June 2019, stating that DowDuPont looks "fairly priced at the current levels" given its two remaining divisions.
04/16/19
04/16/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. HollyFrontier (HFC) downgraded to Sell from Neutral at Goldman Sachs with analyst Neil Mehta saying he now sees a less attractive crude differential environment given a narrower Brent-WTI and WTI-WCS spread forecast in 2019 and 2020. 2. BP (BP) downgraded to Outperform from Top Pick at RBC Capital with analyst Biraj Borkhataria citing valuation. 3. Cisco (CSCO) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Rod Hall saying Cisco has executed well on rolling out its Catalyst 9000 products that have driven "solid" double digit growth in campus switching revenues. 4. DowDuPont (DWDP) downgraded to Sector Perform from Outperform at RBC Capital with analyst Arun Viswanathan citing the impact of the company's spinoff of Dow on April 2nd. 5. EOG Resources (EOG) and EQT Corporation (EQT) downgraded to Neutral from Buy at MKM Partners. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TEL TE Connectivity
$88.64

1.06 (1.21%)

03/28/19
MSCO
03/28/19
NO CHANGE
MSCO
Infineon warning a 'reality check' for semiconductor group, says Morgan Stanley
Morgan Stanley analyst Craig Hettenbach noted that Infineon cut its FY19 revenue guidance by around 3.5% yesterday, citing elevated inventory in China autos and distribution broadly. Hettenbach calls the negative pre-announcement "an important reality check for semis" that calls into question recently building optimism for a second half rebound. Hettenbach maintains a Cautious view on Semis as a group and lists Sensata (ST), NXP Semiconductors (NXPI), TE Connectivity (TEL), Cypress Semiconductor (CY) and ON Semiconductor (ON) as stocks he covers that have meaningful exposure to autos.
11/01/18
RHCO
11/01/18
NO CHANGE
Target $82
RHCO
Hold
TE Connectivity price target lowered to $82 from $104 at SunTrust
SunTrust analyst William Stein lowered his price target on TE Connectivity to $82 and kept his Hold rating, saying that although the company's Q3 results were solid, its FY19 guidance may require another cut. The analyst believes that the management's 3% organic growth outlook may be too high in light of the current macro conditions, even though he is positive on the TE Connectivity's overall execution - particularly in its out-performing auto production segment.
12/04/18
JEFF
12/04/18
INITIATION
Target $84
JEFF
Hold
TE Connectivity initiated with a Hold at Jefferies
Jefferies analyst David Kelley started TE Connectivity with a Hold rating and $84 price target. The analyst sees a "speed bump" in 2019 as production volatility negatively impacts results in the first half of 2019.
03/18/19
JEFF
03/18/19
NO CHANGE
Target $62
JEFF
Buy
Jefferies boosts price targets for Sensata, TE Connectivity
Interior sensors are an underappreciated auto tech growth segment, Jefferies analyst David Kelley tells investors in a research note. With synergies across less cyclical non-auto markets, suppliers with sensor exposure, Sensata Technologies (ST) TE Connectivity ((TEL), are "worth a revisit given favorable scarcity value in the event of prolonged auto downturn," adds the analyst. He remains bullish on Buy-rated Sensata and boosted his price target for the shares to $62 from $59. The analyst boosted his target for TE Connectivity to $84 from $79 but keeps a Hold rating on the shares citing a "tough fiscal comp hurdle."
MRK Merck
$77.50

-1.01 (-1.29%)

03/20/19
SBSH
03/20/19
NO CHANGE
SBSH
Bayer shares likely to remain 'depressed' pending trial success, says Citi
While sentiment will "clearly take a knock" at the second Roundup trial going against Bayer (BAYRY), both verdicts were delivered by juries in California and EUR 22B of litigation risk is already priced into the shares, Citi analyst Peter Verdult tells investors in a research note. The analyst says his legal checks continue to instruct him to be more focused on the upcoming Hall vs. Monsanto trial being held in St Louis from April 1. He says that verdict will better determine whether his estimate of a potential settlement liability of $1B-$6B needs to be refined. However, Bayer shares will "likely remain depressed" until there is evidence of the company prevailing in one or more of the six cases to go to trial in 2019, Verdult contends. He keeps a Buy rating on the stock but prefers other Pharma plays AstraZeneca (AZN), Sanofi (SNY), Novartis (NVS) and Merck (MRK).
02/22/19
CANT
02/22/19
INITIATION
Target $95
CANT
Overweight
Merck initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen started Merck with an Overweight rating and $95 price target. The company's sales growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as its margin expansion opportunities, are underappreciated at current share levels, Chen tells investors in a research note. She expects upward earnings revisions and multiple expansion in 2019 to drive Merck shares higher.
03/11/19
WBLR
03/11/19
NO CHANGE
WBLR
Outperform
William Blair sum-of-the-parts analysis yields $19.80 value for Pfenex
The majority of Pfenex (PFNX) investor focus has been placed on lead asset PF708, the therapeutic equivalent product candidate to Forteo, William Blair analyst Andy Hsieh tells investors in a research note, citing his talks with clients. The analyst, however, sees "potential for significant value" from the company's collaboration with Jazz Pharmaceuticals (JAZZ). The deal with Jazz could provide patients with an alternative to Erwinaze/Erwinase, which currently suffers from significant supply constraints, and CRM197, a carrier protein that is incorporated as an adjuvant in several vaccine candidates, including Merck's (MRK) pneumococcal vaccine, V114, Hsieh writes. Based on these royalties, the analyst conducted a sum-of-the-parts analysis for Pfenex based on discounted cash flow, and the resulting net present value yielded a value of $19.80 per share. The stock closed Monday at $4.26. The analyst believes the company's "value-creating" catalysts this year, including milestone payment from Jazz for the successful tech transfer of PF743 and PF745 and the approval of PF708, coupled with his valuation analysis, affirm his bullish thesis. Hsieh believes Pfenex shares offer one of the best risk/reward symmetries in small-cap biotech and reiterates an Outperform rating on the name.
03/13/19
CANT
03/13/19
NO CHANGE
Target $95
CANT
Overweight
Merck opportunity in China is underappreciated, says Cantor Fitzgerald
After taking a deeper look at the Chinese PD-1 market, Cantor Fitzgerald analyst Louise Chen believes it could equate to billions of sales that are not yet in the forecasts for Merck's Keytruda. She thinks the peak sales potential of PD-1s in China remains underappreciated. China's pharma market can grow to $225B by 2025, which would support a growing PD-1/PD-L1 market, Chen tells investors in a research note titled "Deep Dive into China: A Complicated but Underappreciated Opportunity." The analyst keeps an Overweight rating on Merck with a $95 price target.
TMO Thermo Fisher
$266.00

-11.755 (-4.23%)

03/25/19
DBAB
03/25/19
NO CHANGE
Target $300
DBAB
Buy
Thermo Fisher price target raised to $300 from $275 at Deutsche Bank
Deutsche Bank analyst Dan Leonard raised his price target for Thermo Fisher to $300 from $275 saying the acquisition of Brammer Bio fills the gap in its contract services offering. The analyst believes Thermo Fisher can continue to exceed market growth rates "despite uniquely challenging comps." He says the acquisition supports his thesis and keeps a Buy rating on the shares.
03/26/19
BARD
03/26/19
NO CHANGE
Target $288
BARD
Outperform
Thermo Fisher price target raised to $288 from $270 at Baird
Baird analyst Catherine Ramsey Schulte reiterated an Outperform rating on Thermo Fisher and raised her price target to $288 from $270 following the company's announcement that it will buy Brammer Bio for $1.7B. In a research note to investors, the analyst says she continues to recommend Thermo Fisher as a core holding, and sees room for organic outperformance throughout 2019 as well as the potential for additional M&A.
03/26/19
BTIG
03/26/19
NO CHANGE
Target $310
BTIG
Buy
Thermo Fisher price target raised to $310 from $290 at BTIG
BTIG analyst Sung Ji Nam raised his price target on Thermo Fisher to $310 and kept his Buy rating after its announced $1.7B deal to buy Brammer Bio. The analyst sees "minimal" revenue and earnings impact from the purchase in the near term but sees the company "gaining valuable capabilities to support one of the fastest growing areas within the biopharma end market" as a result of the transaction. Sung Ji Nam concludes that the acquisition makes "financial sense" given Thermo Fisher's "successful foray" into the contract development and manufacturing organization, or CDMO, market.
03/25/19
UBSW
03/25/19
NO CHANGE
Target $305
UBSW
Buy
Thermo Fisher price target raised to $305 from $295 at UBS
UBS analyst Daniel Brennan raised his price target on Thermo Fisher to $305 and kept his Buy rating after meeting with the VP of its Investor Relations last week. The analyst notes that discussions have reflected the company's "healthy markets" and "strong momentum" following 2018's 8% organic growth. Brennan adds that Thermo Fishe's Biopharma business is set to rise even faster after its estimated 14% growth based on its fast-growing segments including bioproduction, clinical trials, and research consumables, even though the company is only guiding high-single-digit growth rate for 2019.

TODAY'S FREE FLY STORIES

WST

West Pharmaceutical

$115.19

(0.00%)

06:07
04/25/19
04/25
06:07
04/25/19
06:07
Earnings
West Pharmaceutical raises FY19 adj. EPS view to $2.80-$2.90 from $2.77-$2.89 »

Consensus $2.86. Backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 07

    May

IRM

Iron Mountain

$35.84

-0.025 (-0.07%)

06:07
04/25/19
04/25
06:07
04/25/19
06:07
Earnings
Breaking Earnings news story on Iron Mountain »

Iron Mountain sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 22

    May

  • 04

    Jun

BDRBF

Bombardier

$0.00

(0.00%)

06:07
04/25/19
04/25
06:07
04/25/19
06:07
Earnings
Bombardier cuts FY19 revenue view to about $17B, consensus $16.26B »

Consolidated revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 14

    May

  • 05

    Jun

NTB

Butterfield

$37.30

-0.18 (-0.48%)

06:07
04/25/19
04/25
06:07
04/25/19
06:07
Hot Stocks
Butterfield to acquire ABN AMRO Channel Islands for approximately $208M »

The Bank of N.T.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 29

    Apr

  • 30

    Apr

WST

West Pharmaceutical

$115.19

(0.00%)

06:06
04/25/19
04/25
06:06
04/25/19
06:06
Earnings
West Pharmaceutical reports Q1 adj. EPS 74c, consensus 65c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 07

    May

ENTG

Entegris

$40.85

0.18 (0.44%)

06:06
04/25/19
04/25
06:06
04/25/19
06:06
Earnings
Entegris sees Q2 non-GAAP EPS 40c-45c, consensus48c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

  • 02

    May

  • 28

    May

WCN

Waste Connections

$89.28

0.01 (0.01%)

06:05
04/25/19
04/25
06:05
04/25/19
06:05
Upgrade
Waste Connections rating change  »

Waste Connections…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 05

    May

  • 17

    May

  • 05

    Jun

BDRBF

Bombardier

$0.00

(0.00%)

06:05
04/25/19
04/25
06:05
04/25/19
06:05
Earnings
Bombardier sees Q1 revenue about $3.5B, consensus $4.76B »

Revenues for Q1 are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 14

    May

  • 05

    Jun

IRM

Iron Mountain

$35.84

-0.025 (-0.07%)

06:05
04/25/19
04/25
06:05
04/25/19
06:05
Earnings
Iron Mountain reports Q1 adj. EPS 17c, consensus 24c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 22

    May

  • 04

    Jun

ENTG

Entegris

$40.85

0.18 (0.44%)

06:04
04/25/19
04/25
06:04
04/25/19
06:04
Recommendations
Entegris analyst commentary  »

Entegris reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

  • 02

    May

  • 28

    May

PTEN

Patterson-UTI

$15.13

-0.71 (-4.48%)

06:04
04/25/19
04/25
06:04
04/25/19
06:04
Earnings
Patterson-UTI reports Q1 EPS (14c), consensus (21c) »

Reports Q1 revenue $704M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 22

    May

TER

Teradyne

$47.99

3.39 (7.60%)

06:03
04/25/19
04/25
06:03
04/25/19
06:03
Upgrade
Teradyne rating change  »

Teradyne upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 29

    May

VMI

Valmont

$132.99

1.845 (1.41%)

06:03
04/25/19
04/25
06:03
04/25/19
06:03
Upgrade
Valmont rating change  »

Valmont upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 24

    Jul

DHI

D.R. Horton

$46.67

0.275 (0.59%)

06:03
04/25/19
04/25
06:03
04/25/19
06:03
Hot Stocks
D.R. Horton sees FY19 homes closed 55,000-56,000 »

Sees FY19: Effective tax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

GRA

W.R. Grace

$75.21

-1.225 (-1.60%)

, FTI

TechnipFMC

$24.77

-0.66 (-2.60%)

06:03
04/25/19
04/25
06:03
04/25/19
06:03
Hot Stocks
W.R. Grace and TechnipFMC collaborating in high yield cracking process »

W. R. Grace (GRA) has…

GRA

W.R. Grace

$75.21

-1.225 (-1.60%)

FTI

TechnipFMC

$24.77

-0.66 (-2.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 08

    May

CUI

CUI Global

$1.17

-0.02 (-1.68%)

06:03
04/25/19
04/25
06:03
04/25/19
06:03
Hot Stocks
CUI Global subsidiary secures GasPT orders from Samson »

CUI Global announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OXY

Occidental Petroleum

$62.00

-0.35 (-0.56%)

06:03
04/25/19
04/25
06:03
04/25/19
06:03
Downgrade
Occidental Petroleum rating change  »

Occidental Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 07

    May

  • 10

    May

  • 29

    May

DHI

D.R. Horton

$46.67

0.275 (0.59%)

06:02
04/25/19
04/25
06:02
04/25/19
06:02
Earnings
Breaking Earnings news story on D.R. Horton »

D.R. Horton sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

DHI

D.R. Horton

$46.67

0.275 (0.59%)

06:01
04/25/19
04/25
06:01
04/25/19
06:01
Earnings
D.R. Horton reports Q2 EPS 93c, consensus 86c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MSFT

Microsoft

$125.00

-0.5 (-0.40%)

06:01
04/25/19
04/25
06:01
04/25/19
06:01
Recommendations
Microsoft analyst commentary  »

Microsoft price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 03

    Jun

  • 03

    Jun

  • 08

    Jun

  • 10

    Jun

  • 23

    Jun

  • 06

    Aug

GOOG

Alphabet

$1,255.22

-9.27 (-0.73%)

, GOOGL

Alphabet Class A

$1,260.07

-10.53 (-0.83%)

06:01
04/25/19
04/25
06:01
04/25/19
06:01
Hot Stocks
SoftBank subsidiary HAPSMobile invests $125M in Alphabet's Loon »

SoftBank Corp.'s…

GOOG

Alphabet

$1,255.22

-9.27 (-0.73%)

GOOGL

Alphabet Class A

$1,260.07

-10.53 (-0.83%)

SFTBF

SoftBank

$0.00

(0.00%)

AVAV

AeroVironment

$67.99

-0.74 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 29

    Apr

  • 29

    Apr

  • 14

    May

  • 29

    May

  • 30

    May

  • 31

    May

  • 05

    Jun

  • 27

    Oct

ALLE

Allegion

$95.50

-0.45 (-0.47%)

06:00
04/25/19
04/25
06:00
04/25/19
06:00
Earnings
Allegion backs FY19 adj. EPS $4.75-$4.90, consensus $4.86 »

Backs FY19 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LTXB

LegacyTexas Financial

$38.05

-3.13 (-7.60%)

05:59
04/25/19
04/25
05:59
04/25/19
05:59
Upgrade
LegacyTexas Financial rating change  »

LegacyTexas upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 20

    May

FB

Facebook

$182.64

-1.13 (-0.61%)

05:59
04/25/19
04/25
05:59
04/25/19
05:59
Recommendations
Facebook analyst commentary at Mizuho »

Facebook price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    May

  • 03

    Jun

AGR

Avangrid

$52.60

0.245 (0.47%)

05:59
04/25/19
04/25
05:59
04/25/19
05:59
Downgrade
Avangrid rating change  »

Avangrid downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 21

    May

  • 21

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.